露丝3月, PhD, is Senior Vice-President of AstraZeneca’s 精密医学 函数.

As a member of the senior leadership team in AstraZeneca’s R&D肿瘤学 group, I am accountable for delivering diagnostics across AstraZeneca’s R&D pipeline to match targeted medicines to those patients most likely to benefit.

I have led the development of AstraZeneca’s industry-leading capability in precision medicine, with 16 diagnostics launched linked to 4 AstraZeneca medicines since 2014. 精密医学 is now applied in >90% of AstraZeneca’s clinical pipeline across all main therapy areas - oncology, CVRM, 呼吸系统疾病.

我还领导了一种创新的诊断方法, developing technologies that best fit the patient’s care pathway. 除了, I have led over $185M investment with diagnostic partners, 包括分子诊断, 组织诊断, next generation sequencing and point of care diagnostics.

我和我的团队开创了许多行业第一:

  • 1st drug label extension based on circulating tumour DNA (ctDNA), making targeted therapy available to up to 40% of patients with lung cancer who cannot provide a solid tumour tissue sample
  • 1st laboratory based companion diagnostic (which detects thousands of mutations in BRCA genes classified through a diagnostic algorithm)
  • 1st companion diagnostic based on both ctDNA and tissue in the resistance setting
  • 1st 在炎症中被认可的护理诊断点
  • 1st prototype point of care diagnostic for eosinophilic asthma

I am a genomics specialist with over 50 patents and publications and I drew on my extensive academic research to lead the first genome-wide single-nucleotide polymorphism analysis of a safety biomarker to be submitted to the FDA.

  Personalised medicine: transforming the way we use medicine

个性化医疗的巨大进步, 在肿瘤学, has been the realisation that some tumours are driven by individual genes. 所以如果你能找出这些是哪些基因, 你可以研发出对那个肿瘤最有效的药物, and then select patients that are best for that medicine.

露丝3月 精密医学高级副总裁，R&D肿瘤学
露丝

最新的项目

精准定位药物

世界领先的基因组战略

AstraZeneca/ MedImmune’s Genomics Initiative aims to analyse 2 million genomes by 2026, 包括测序500,000 samples from patients in our clinical trials and integrating genomics with clinical data. Achieving these ambitious goals involves working with a global network of two industrial and seven academic partners including Columbia University Institute of Genomics Medicine, U.S. 以及美国剑桥大学.K.

首次循环肿瘤DNA批准

First regulatory label in the world to include use of circulating tumour DNA (ctDNA) for mutation testing (2014), enabling testing for approximately 25% of eligible lung cancer patients in whom a tumour sample is not evaluable

  特色的出版物

Drug target genes associated with clinical phenotypes in the genetically isolated population of Finland more likely to succeed in pharmaceutical development

Drug target genes associated with clinical phenotypes in the genetically isolated population of Finland more likely to succeed in pharmaceutical development. R 3月, 米达, C麋鹿, 一个普拉特, M Alanen-Kinnunen, 年代Lemmela,  V Salomaa, P Jousilahti, 米达利, D Goldstein和A Palotie. ASHG 2017会议摘要.

Lessons learned from the fate of AstraZeneca's drug pipeline

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. D Cook, D Brown, R Alexander, R E March, P Morgan, G Satterthwaite & 潘加罗斯先生. Nature Reviews Drug Discovery 13, 419-431 (June 2014) | doi:10.1038 / nrd4309

阅读更多

Genome-wide pharmacogenetic investigation of a hepatic adverse event

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. 一个Kindmark, 一个Jawaid, C·G·哈布伦, B J Barratt, Bengtsson, B·安德森, S•, K。E。cederbrandt, N J吉布森, M·阿姆斯特朗, M E Lagerström-Fermér, 一个Dellsen, 布朗先生, 米桑顿, C公爵, S C詹金斯, M A Firth, 哈罗德先生, T H面板, 比尔-克拉森先生, L·R·卡登和R·E·马奇. The Pharmacogenomics Journal (2008) 8, 186–195; doi:10.1038/sj.部的颞顶联合区的.6500458

阅读更多

I believe personalised healthcare is the future of medicine; it allows us to use the latest diagnostic science to target medicines to patients most likely to benefit.

露丝3月
精密医学

精密医学 – targeting the right medicine to the right patient at the right time – is now a critical part of our approach to drug discovery.

澳门在线赌城娱乐

故事 from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.

澳门第一赌城在线娱乐的人民

澳门第一赌城在线娱乐的人民 share a common purpose: to push the boundaries of science to deliver life-changing medicines.

加入澳门在线赌城娱乐

并帮助澳门第一赌城在线娱乐提供改变生活的药物 

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.

澳门在线赌城娱乐的职业